Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.1 USD | -4.43% | -6.82% | -40.36% |
16/04 | SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update | CI |
02/04 | HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 37.82M 3.16B |
---|---|---|---|---|---|
Net income 2024 * | -45M -3.75B | Net income 2025 * | -57M -4.76B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.95
x | P/E ratio 2025 * |
-0.66
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.39% |
1 day | -4.43% | ||
1 week | -6.82% | ||
Current month | -4.43% | ||
1 month | -4.43% | ||
3 months | -30.51% | ||
6 months | -59.00% | ||
Current year | -40.36% |
Managers | Title | Age | Since |
---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 22/21/22 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 22/21/22 |
Michael King
DFI | Director of Finance/CFO | 63 | 30/23/30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 68 | 22/21/22 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 22/21/22 |
Erick Lucera
BRD | Director/Board Member | 57 | 03/23/03 |
Date | Price | Change | Volume |
---|---|---|---|
01/24/01 | 4.1 | -4.43% | 336 |
30/24/30 | 4.29 | +2.39% | 805 |
29/24/29 | 4.19 | -1.41% | 2,681 |
26/24/26 | 4.25 | +5.98% | 4,877 |
25/24/25 | 4.01 | -8.86% | 794 |
Delayed Quote Nasdaq, May 02, 2024 at 02:00 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.36% | 37.82M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.38% | 22.25B | |
-14.77% | 21.68B | |
-7.77% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- SABS Stock